Naohiro Tsuyama

Naohiro Tsuyama

Auto-generated profile, based on publicly available information

Naohiro Tsuyama

Department of Radiation Life Sciences, Fukushima Medical University School of Medicine, Fukushima, Japan

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2015 in Nature Protocols
Verified
Journal Article
Closed access
TFTakashi Fujii
Takashi Fujii
SMShuichi Matsuda
Shuichi Matsuda
MTMónica Lorenzo Tejedor
Mónica Lorenzo Tejedor
TETsuyoshi Esaki
Tsuyoshi Esaki
ISIwao Sakane
Iwao Sakane
TMTsutomu Masujima
Tsutomu Masujima

15 April 2005 in Blood
Verified
Journal Article
Open access
PDF file
FLFu-Jun Li
Fu-Jun Li
NTNaohiro Tsuyama
Naohiro Tsuyama
HIHideaki Ishikawa
Hideaki Ishikawa
MOMasanori Obata
Masanori Obata
SASaeid Abroun
Saeid Abroun
MKMichio M. Kawano
Michio M. Kawano
CD45, a receptor-type tyrosine phosphatase, is required for interleukin-6 (IL-6)-induced proliferation in human myeloma cells, which express the shortest isoform, CD45RO, but not the longest isoform, CD45RA. Here, we showed that IL-6 induced the translocation of CD45 to lipid rafts in an isoform-dependent manner. In myeloma cells, CD45RO was translocated to lipid rafts more rapidly than CD45RB, but exogenously expressed CD45RA was not translocated. When an IL-6Rα-transfected B-cell line was stimulated with IL-6, CD45RA was not translocated, although CD45RB was. We further confirmed that the translocated CD45 bound to IL-6Rα, Lyn, and flotillin-2, and this was followed by the dephosphorylation of the negative regulatory Tyr507 of Lyn. CD45 also bound to phosphoprotein associated with glycosphingolipid-enriched microdomains (PAGs), which were subsequently dephosphorylated, resulting in the release of C-terminal src kinase (Csk) from lipid rafts. Therefore, these results indicate that a rapid translocation of CD45RO to lipid rafts may be responsible for IL-6-induced proliferation, and that the change from CD45RA to CD45RO confers the ability to respond to IL-6 in human myeloma cells. (Blood. 2005;105:3295-3302)

15 June 2004 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SKSeishi Kyoizumi
Seishi Kyoizumi
TOTakaaki Ohara
Takaaki Ohara
YKYoichiro Kusunoki
Yoichiro Kusunoki
THTomonori Hayashi
Tomonori Hayashi
KKKazuaki Koyama
Kazuaki Koyama
NTNaohiro Tsuyama
Naohiro Tsuyama
We have used HSCA-2, an mAb that recognizes a sialic acid-dependent epitope on the low molecular mass (∼115-kDa) glycoform of CD43 that is expressed in resting T and NK cells, to examine the expression characteristics and stimulatory functions of CD43 in human CD4+ memory T cells. Having previously reported that the memory cells that respond to recall Ags in a CD4+CD45RO+ T cell population almost all belong to a subset whose surface CD43 expression levels are elevated, we now find that exposing these same memory T cells to HSCA-2 mAb markedly increases their proliferative responsiveness to recall Ags. We think it unlikely that this increase in responsiveness is a result of CD43-mediated monocyte activation, especially given that the HSCA-2 mAb differs from all previously used CD43 mAbs in having no obvious binding specificity for monocyte CD43. Predictably, treatment with HSCA-2 mAb did not lead to significant recall responses in CD4+CD45RO+ T cells, whose CD43 expression levels were similar to or lower than those of naive cells. Other experiments indicated that the HSCA-2 mAb was capable of enhancing the proliferative responsiveness of CD4+ memory T cells that had been exposed to polyclonal stimulation by monocyte-bound CD3 mAb and could also act in synergy with CD28 mAb to enhance the responsiveness of CD4+ T cells to CD3 stimulation. Taken together, these findings suggest that the CD43 molecules expressed on CD4+ memory T cells may be capable of enhancing the costimulatory signaling and hence providing accessory functions to TCR-mediated activation processes.

10 May 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FKFumihiko Kawamura
Fumihiko Kawamura
MIMakoto Inaki
Makoto Inaki
AKAtsushi Katafuchi
Atsushi Katafuchi
YAYu Abe
Yu Abe
NTNaohiro Tsuyama
Naohiro Tsuyama
ASAkira Sakai
Akira Sakai
B cell derived induced pluripotent stem cells (BiPSCs) were recently established from peripheral blood B cells by the simultaneous transfection of Yamanaka factors (Oct3/4, Sox2, Klf4, c-Myc) and C/EBPα using a Sendai virus vector. Here, using a different method, we established BiPSCs with immunoglobulin heavy chain (IgH) gene rearrangement from normal B cells purified from lymph nodes. The critical points of our method are pre-stimulation of B cells with IL-21 and CD40-ligand (CD40L), followed by consecutive transfection of highly concentrated Yamanaka factors using a retroviral vector. Following each transfection the cells were centrifuged onto a retronectin coated plate and the activated by IL-4, IL-2, and CD40L. Furthermore, we established BiPSCs (BiPSC-A) in which activation-induced cytidine deaminase (AID) could be induced using the doxycycline-controlled. Both the parental BiPSC and BiPSC-A showed the capability of differentiating into hematopoietic progenitor cells (HPCs) based on confirmation of CD34 expression and colony-formation from CD34-positive cells. The findings that BiPSC-A can differentiate into HPCs suggest that there is a possibility that induction of AID expression would result in chromosomal translocations in the process of differentiation from BiPSCs, and therefore that these BiPSCs could be useful in elucidating the tumor origin of abnormal B cells in myelomagenesis.

16 November 2004 in Blood
Verified
Journal Article
Open access
KOKen-Ichiro Otsuyama
Ken-Ichiro Otsuyama
ZMZi Ma
Zi Ma
SLShangqin Liu
Shangqin Liu
FLFu-Jun Li
Fu-Jun Li
SASaeid Abroun
Saeid Abroun
MKMichio M. Kawano
Michio M. Kawano
Growth expansion of monoclonal plasma cells (myeloma cells) in the bone marrow (BM) is triggered by increase in serum interleukin-6 (IL-6). Indeed, high levels of IL-6 have been found in the serum of patients with progressive multiple myeloma (MM), and a reduction of the tumor cell mass has been reported by inhibition of myeloma cell proliferation with anti-IL-6 antibodies. On the other hand, IL-6 is considered to increase physiologically in its serum level along with age, and the age-related increase in serum IL-6 could be related to the age-dependent diseases such as rheumatoid arthritis, atherosclerosis, Alzheimer’s disease and B cell malignancies including myelomas. Recent reports also show that the age-associated decline in the serum level of an adrenal sex hormone, dehydroepiandrosterone sulfate (DHEA-S), is closely related to the increase in serum IL-6. Here, we show that DHEA-S is decreased significantly more than that by physiological decline with age in overt myeloma, but not in other lymphoid malignancies such as malignant lymphoma or macroglobulinemia. DHEA-S as well as DHEA suppressed IL-6 production from a BM stromal cell line, KM-102, and bone marrow mononuclear cells from patients with MM. Furthermore, DHEA inhibited in vitro growth of the U-266 cell line and primary myeloma cells from the patients, and also in vivo growth of U-266 cells intraperitoneally implanted in SCID-hIL6 transgenic mice. DHEA upregulated the expression of peroxisome proliferator activated receptor (PPAR)β and IκBα gene in myeloma cells and BM stromal cells, which could explain the suppressive effect of DHEA on IL-6 production through the downregulation of NF-κB activity. PPAR agonists such as troglitazone, carbacyclin and WY14643, also inhibited the growth of myeloma cell lines and primary myeloma cells. Therefore, these findings suggest that DHEA has a capability of inhibiting the growth of myeloma cells and IL-6 production of bone marrow mononuclear cells through activation of PPAR and/or suppression of NFκB activity, and inversely a decreased level of DHEA and DHEA-S could upregulate IL-6 activity, which could be responsible for progression of myeloma cells.

16 November 2004 in Blood
Verified
Journal Article
Open access
XZXu Zheng
Xu Zheng
HIHideaki Ishikawa
Hideaki Ishikawa
NTNaohiro Tsuyama
Naohiro Tsuyama
SASaeid Abroun
Saeid Abroun
SLShangqin Liu
Shangqin Liu
MKMichio M. Kawano
Michio M. Kawano
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.